.01). The effectiveness of corticosteroids was conclusively proved in placebo-controlled trials: There was significant reduction in duration of fever from a mean of 6 days to 3 days when prednisolone was given at 40-80 mg/day for 12 days [9] [10] [11] [12] , abnormal hematologic findings were reduced from 7 to 3 weeks, and there was some relief from pharyngitis symptoms. However, scattered case reports of an increased incidence of myocarditis and encephalitis have hampered general use of steroids in the treatment of 1M [13, 14] . These complications were possibly due to a steroid-induced inhibition of EBV-specific cellular immune responses and increased viral replication [14, 15] . Hence, a combination of antiviral and steroid therapy in the early stages of 1M might reduce clinical severity due to the immunomodulatory effect of steroid treatment without having the detrimental effects of steroid-enhanced viral replication [15] .
We investigated the efficacy and safety of combined treatment with acyclovir and prednisolone on acute 1M in a doubleblind study. Patients with 1M, who had been ill~7 days, were treated with acyclovir and prednisolone or acyclovir and placebo for 10 days. Clinical parameters, oropharyngeal EBV shedding in saliva, and the development of HLA-restricted EBV-specific cellular immune reactivity were assessed.
Patients and Methods
The double-blind, placebo-controlled trial was done between 1988 and 1991 at the Department of Infectious Diseases, Danderyd and Roslagstull Hospital, Sweden, and East Birmingham Hospital (since renamed Birmingham Heartlands Hospital), United Kingdom. Patients [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] years old who were suspected of having 1M were referred to the hospitals by primary health practitioners. Patients were eligible for the study if they had clinical features of 1M (sore throat, lymphadenopathy, and general malaise), symp-toms~7 days, baseline oral temperature> 37.5°C, atypical mononuclear cells in peripheral blood, and a positive heterophil antibody test. We excluded women who were pregnant, breast-feeding, or of childbearing potential and not adequately protected by contraception and patients with current or past peptic ulceration, diabetes mellitus, hypertension, glaucoma, tuberculosis, or any condition in which steroid therapy is contraindicated and those who had received antiviral or steroid therapy in the preceding 2 weeks, those receiving phenytoin, phenobarbitone, ephedrine, or rifampicin, and those with impaired renal function (serum creatinine> 120 pmol/L).
Two computer-generated randomization codes, one for the United Kingdom and one for the Swedish combined center, were prepared by the Department of Statistics, Wellcome Research Laboratories (Beckenham, UK). The randomization code was open to the hospital chief pharmacist but blinded to the investigators. After study entry and clinical examination, patients were allocated to oral or intravenous (iv) treatment, depending upon their ability to swallow and whether they were vomiting. Patients on oral or iv treatment were entered on opposite ends of the randomization code. About 40% of the patients were also randomly selected for the virologic assessments detailed below.
All patients were entered in sequential order according to the randomization code to receive a l O-day course of treatment with acyclovir plus prednisolone or placebo. The acyclovir treatment was 800 mg orally 5 times/day or 5 mg/kg as a 1-h iv infusion every 8 h until oral medication could be taken. The prednisolone dosage was dependent on the patient's weight at study entry. Oral steroid treatment consisted of 0.7 mg/kg prednisolone daily (the total daily dosage was rounded to the nearest 5 mg) for the first 4 days; this was reduced by 0.1 mg/kg/day until prednisolone was withdrawn on day 10. We used an equivalent dosing schedule of continuous iv hydrocortisone, starting at 3.5 mg/kg/day, for patients who required iv therapy. Patients randomized to receive placebos were given matching placebo tablets or infusions.
Vials containing freeze-dried preparations of 250 mg of acyclovir (sodium salt) or placebo for reconstitution with 10 mL of water for injection B.P. (British Pharmacopoeia) or sodium chloride infusion B.P., tablets containing 800 mg of acyclovir or matching placebo, and 5 mg tablets of prednisolone or matching placebo were supplied, labeled, and coded by Well come Research Laboratories and Kabi (Stockholm) and packed in similarly labeled boxes. Hydrocortisone and matching saline for iv infusion were prepared by the hospital pharmacies.
During the trial, patients were not allowed concomitant therapy with nonsteroidal antiinflammatory drugs.
Clinical observations. Patients were examined clinically daily while hospitalized, otherwise on days 3 or 4, 7, 9, or 10 and 14 and thereafter at weekly intervals until their symptoms and signs had returned to normal. Follow-up assessments were done at the hospital at months 3 and 6. At each assessment, the following symptoms and signs were recorded and scored: general health (0 = well, 1 = slightly unwell, 2 = moderately ill, J = severely ill), psychologic well being (0 = normal, 1 = slightly depressed, 2 = depressed, 3 = very depressed), sore or painful throat (0 = none, I = mild, 2 = moderate, 3 = severe), difficulty in breathing (yes/ no), difficulty in swallowing (0 = none, I = solids, 2 = fluids, 3 = saliva), oral temperature, body weight, tonsillar swelling (0 = none, 1 = mild, 2 = moderate, 3 = severe), tonsillar exudate (yes/ no), cervical lymph nodes enlarged (yes/no) or tender (yes/no), liver enlarged (yes/no) or tender (yes/no), spleen enlarged (yes/ no), and rash present (yes/no). Until symptoms and signs resolved (i.e., while weekly follow-ups continued), patients conducted daily self-assessments and recorded their symptoms on a diary card. In addition to the symptoms listed above, patients recorded tiredness (0 = none, 1 = mild, 2 = moderate, 3 = severe), difficulty in sleeping (yes/no), headache (yes/no), nocturnal sweating (yes/no), self-medications taken, and whether the day was missed from school or work (if unemployed or on holiday, whether the day would have been missed).
Serology. Blood was taken for serologic measurements on days 0 and 14 and at 3 and 6 months of follow-up. Heterophile antibodies were determined by the Davidsohn and Lee test [16] . Specific EBV serology was done for all patients and included titration of antibodies to EBV-associated nuclear antigens (EBNA) 1 and 2 and IgM and IgG antibodies to viral capsid antigen (VCA). These tests were done at the Department of Virology, Swedish Institute for Infectious Disease Control, Stockholm, and at the Regional Department of Immunology, East Birmingham Hospital. The methods, which have been described, are highly specific for diagnosing primary EBV infection [17] . The diagnosis of acute EBY infection was confirmed by demonstration of 19M antibody against VCA and titers of antibody to EBNAI ::::; 1:5 on days 0 and 14.
Thirty-four patients (8, UK; 26, Sweden) were randomly selected for virologic and immunologic assessments on days 0,7, 9 or 10, and 14 and months 3 (day 90) and 6 (day 180).
Virologic assessment. Semi quantification of oropharyngeal EBY shedding was done with throat washings. A patient was asked not to swallow for 5 min and then to rinse his or her mouth for 30 s with 10 mL of RPMl 1640 medium (GIBCO, Paisley, UK). Bacteria and detritus were removed by centrifugation at 1000 g for 10 min. Ten percent fetal calf serum (FCS) was added to the supernatants before they were frozen at -70°C. After thawing, saliva samples were diluted 10 I, 10 2 , and 10 3 and added to microtiter wells containing Ficoll-separated lymphocytes from umbilical cord blood. Aliquots of 2 X 10 5 cells in 0.2 mL of medium containing 10% FCS, 20 U of penicillin, and 20 /-lg of streptomycin were used, and each saliva dilution was distributed in 10 wells and cultured 4-8 weeks.
The presence of virus in oropharyngeal washings was detected by transformation of cord blood cells and by screening for the induction of EBNA in the same cord blood cells 7 days after infection with undiluted throat washing samples as described by Reedman and Klein [18] . The virus titer providing 50% transformation (TT 50 ) after 4~8 weeks was determined from the virus dilution curves. Thus, a semiquantitative measurement of the amount of oropharyngeal virus was obtained for each sample by two assays. The correlation between the TT 50 and the percentage of EBNA-positive cells was high (r = .92).
Precursor frequency of in vivo EBV-infected B lymphocytes.
For a spontaneous outgrowth assay, lymphocytes were separated from patients' peripheral blood on days 0 and 180 by centrifugation of heparinized whole blood over a Ficoll-Isopaque cushion (1500 g for 30 min at 20°C) and stored in liquid nitrogen. The thawed lymphocytes were cultured in 10% FCS for 6 weeks at concentrations of 6 X 10 5-5 X 10 4 cells/well. Each dilution was distributed in 10 wells of a flat-bottomed microtiter plate. This method (de- scribed in [19] ) allows spontaneous outgrowth of B lymphocytes latently infected in vivo (if present in a detectable amount) to transformed lymphoblastoid cells [6] . Such cells were visualized by inverse microscope. The transformed cells were checked by staining for EBNA positivity; the geographic mean value indicated the cell concentration that induced a 50% transformation rate (TC so ). The number of wells with positive transformation correlated with the frequency of EBV-infected B lymphocytes in vivo [15] . Cells exposed to the B95-8 laboratory strain of EBV were used as positive controls.
Immunologic assessment. We used an outgrowth inhibition assay to determine EBV-specific cellular immunity. Lymphocytes obtained at enrollment and on day 180 were thawed and added to microwells at four different concentrations (2 X 10 4-4 X l O" cells/ well) in 10% FCS. Aliquots containing~10 6 infectious U/mL EBV (B95-8) were added to cell suspensions that were cultured 6 weeks to allow outgrowth into lymphoblastoid cell lines. If EBV immune T cells were present in the patient's blood, they would inhibit outgrowth of EBV-infected B lymphocytes. The strength of this regression correlated with individual concentrations ofEBV immune T cells in vivo and could be quantified in terms of the minimum number of added cells required to achieve a 50% inhibition of outgrowth of EBV -transformed cells (CT50)' The lower the cell concentration that inhibited outgrowth, the higher the in vivo proportion of EBV immune T cells [6] .
Safety. All patients were questioned about and examined for adverse reactions. Hematologic and biochemical parameters were measured on day 0 during treatment and at the 14-day assessment.
Statistical methods. We plotted Kaplan-Meier curves for duration of sore throat, duration of weight loss, absence from work! school, and general health with respect to time, adjusted for center using survival analysis and Mantel-Cox statistics. For viral shedding, the Mann-Whitney rank test was used to compare the 2 groups. The study was designed to have sufficient power to detect a 66% reduction in median duration of viral shedding. 
Results
During the 3-year study period, 94 patients (32 from Britain, 62 from Sweden) were randomized to participate in the study. Of the 94, 8 were excluded from evaluation: 6 because of wrong diagnoses and 1 each because of insufficiently elevated temperature at enrollment and symptoms present~7 days before enrollment. Of the 6 patients with the wrong diagnosis, 1 had primary herpes simplex infection, 2 had adenovirus infections, and 3 had illnesses of unknown etiology.
The diagnosis of primary EBV infection was serologically verified by the finding of IgM anti-VeA antibodies and anti-EBNA antibody titer of < 1:lOon days 0 and 14 in the remaining 86 patients. Of these, 43 were randomized to acyclovir-prednisolone and 43 to placebo. Four patients later withdrew from the study (2 on day 2 and 1 each on days 7 and 10); another was given prednisolone openly by his general practitioner on day 6 because of clinical deterioration. In total, 81 patients were followed clinically until day 14. Fifty-two subjects were also seen at the 3-month follow-up; 49 were followed 6 months.
At enrollment, the 2 groups were comparable in terms of age, duration of illness, and severity of disease as assessed by clinical and laboratory parameters (tables 1, 2). The 2 groups had no differences in IgO and IgM antibody titers against YeA.
Clinical Findings
We decided not to use duration of fever as a primary end point in the study, since fever may have been directly affected by steroid treatment through an inhibiting effect on interleukin (IL )-1, tumor necrosis factor (TNF)-a, and prostaglandin E 1 production. Fever was included in the general health assessment. There were no statistically significant differences between the groups in the resolution of any clinical parameter during the study period. Time to resolution of sore throat (figure Table 2 . Laboratory parameters of evaluable patients with infectious mononucleosis enrollment (n = 86). 1A) and general health, body weight (figure 1B), and time away from school/work (figure 1C) were plotted in KaplanMeyer curves. Sore throat. At follow-up days 2~4, 4 (9%) of 44 patients in the acyclovir-steroid group had severe pharyngeal discomfort (score = 3) compared with 10 (24%) of 41 in the placebo group. At the 14-day follow-up, 95% of each group no longer had a sore throat. The median duration of sore throat was Days after enrolment 9 days for acyclovir-steroid patients and 7 days for placebo recipients (figure lA).
Body weight. At day 14 of follow-up, 13 (31 %) of 42 acyclovir-steroid patients had not yet regained baseline weight compared with 15 (40.5%) of 37 placebo recipients ( figure 1B) .
Duration ofillness. In the acyclovir-steroid group, the median duration of absence from school/work was 13 days (range, 2-42; mean, 15 ± 2 days). The placebo group had a corre- sponding median time of 11 days (range, 1-98; mean, 17 ± 4 days; figure 1C ). The parameters general health, sore throat, and tender cervical lymph nodes, respectively, were improved by day 3 in 40%, 70%, and 46% of patients in the acyclovir-steroid group and in 26%, 40%, and 28% of those in the placebo group. The hazard ratio, which measured the time for improved general health in the acyclovir-steroid group relative to the placebo group, was 0.01, suggesting a trend in favor of acyclovir-steroid treatment. By day 7 and thereafter, this difference was no longer visible.
Other Clinical Complications
One patient in the acyclovir-steroid group had signs of encephalitis at enrollment. He recovered without any sequelae. One patient (also in the acyclovir-steroid group) had facial palsy at enrollment and on day 9 when the patient withdrew from the study.
Laboratory Parameters
Hemoglobin concentration, total white blood cell count, presence of atypical lymphocytes (>5%), platelet count, prothrombin time, bilirubin, liver enzymes (alkaline phosphatase, aspartate and alanine aminotransferase), and creatinine levels were comparable in the 2 groups at baseline. Two patients had clinical jaundice at enrollment (both in the acyclovirsteroid group); 70 (83%) of 84 patients had elevated liver alanine aminotransferase levels (0.8-26.5 }-lkat/L; normal, <0.7 mkat/L).
The decline in the total white blood cell count was somewhat faster in the placebo group, possibly due to the well-recognized steroid effect on granulocyte chemotaxis. The blood film was followed in more detail in 54 Swedish patients (27 in each treatment arm). The number of atypical lymphocytes (mean, 20% :t 11% in both groups at enrollment) normalized more rapidly in the acyclovir-steroid group. On treatment day 7, patients who received acyclovir and steroid had 8% :t 11% atypical lymphocytes and those in the placebo arm had 12% ± 10%. Platelets also normalized faster in acyclovir-steroid recipients than in the placebo group (data not shown). Neither group had evidence of renal impairment (table 3) .
Virology
Oropharyngeal EBV shedding. We found no statistically significant differences between the 2 groups in median values of oropharyngeal EBV shedding at enrollment (figure 2). Acyclovir and prednisolone treatment effectively suppressed oropharyngeal EBV replication, with a significant reduction of the EBV titer of the mouthwash samples at assessment days 7 and 10, respectively (P = .02, Mann-Whitney rank test). However, this effect was transient, and EBV shedding returned to baseline values at day 14, after acyclovir-prednisolone treatment was discontinued. There were no significant differences between the 2 groups thereafter (figure 2). 
Immunology
Humoral immune response. The diagnosis of primary EBV infection was serologically verified in all 86 evaluable patients.
All patients had IgM and IgG vex and EBNA negativity. Of the 94 enrolled patients, 88 had a positive heterophile test on day O. Eighty-seven cases of 1M were verified with EBVspecific serology. One patient had a false-positive heterophile test and did not have a primary EBV infection. Titration of antibody levels to IgM and IgG classes against VCA was done at study entry. There were no differences between groups.
Cellular immune response. Previous studies have shown that almost 100% of 1M patients lack HLA-specific T cellmediated EBV immunity at onset of disease [2, 3] . This was investigated at enrollment and at 180 days. The outgrowth inhibition assay determined the incidence of HLA-restricted T cell-mediated immunity against autologous EBV-infected B cells. Before treatment only 2 of 35 patients had evidence of outgrowth inhibition. All patients investigated Discussion [25] that express a number of adhesion receptors, produce various intracellular cytokines, and up-regulate oncogenes, thus establishing intrinsic growth factors [25, 26] . The current concept of the pathogenesis of 1M is that these cells are extremely immunogenic and trigger profound activation of the cellular immune response [26, 27] . The activation is initially polyclonal and HLA-unrestricted with limited specificity directed against EBV -derived antigens [21, 25] . We studied the local cytokine response in tonsillar tissue in patients with acute 1M and found that interferon (IFN)-y, IL-2 and -6, and TNF-a were the dominant cytokines [27, 28] . We previously found that pharmacologic steroid doses induce a dose-dependent increase in viral replication in EBV-infected cells [15] . Thus, it might be possible that addition of steroids to acyclovir for 1M therapy would limit the antiviral effect of acyclovir.
Results of the present study clearly showed that this was not the case and that acyclovir combined with prednisolone efficiently inhibited EBV replication in the oropharynx. Furthermore, the number of atypical lymphocytes circulating in the blood declined more rapidly in patients treated with acyclovir and prednisolone. Similar results have been reported in studies of iv or oral acyclovir therapy alone [6, 7] . The steroid therapy also did not alter the natural cellular immunity against EBV or the precursor frequency of in vivo-infected B lymphocytes analyzed 6 months after the acute illness. Thus, in the pharmacologic doses of prednisolone used in this study, development of HLA-restricted cytotoxic T cells was not affected.
In an earlier study, the same oral dose of acyclovir was shown to significantly inhibit viral shedding in the oropharynx [7] . The major limitation of acyclovir is the low grade of absorption (10%-20%). This problem can be overcome by administration of the prodrug valacyclovir [29] . However, no augmented antiviral effect can be expected with this drug compared with results obtained with high-dose iv acyclovir [6] . Penciclovir was recently shown to effectively inhibit the productive replication cycle ofEBV in vitro and may be an alternative treatment regimen [30] . However, at the acyclovir dosage used in this study, EBV replication in the oropharynx was significantly suppressed. Thus, we believe that lack of clinical efficacy in the current study was due to mechanisms other than insufficient antiviral effect on infected cells.
In the present study, we did not find any significant clinical effect on duration ofoverall symptoms of acute 1M by treatment with a combination of acyclovir and prednisolone. This may be explained by the findings of Luedke and Cerami [31] , who showed that steroid-mediated down-regulation of monokine production in macrophages could not be blocked in the presence of IFN-y. Indeed, we recently showed that IFN-y is elevated in serum, circulating T cells, and tonsil tissue at the onset of disease [26] [27] [28] . Thus, the induced IFN-y expression may be an explanation for the lack of clinical effects of prednisolone in this study. However, there was a trend in favor of such treatment: Individual symptoms and signs improved during the Primary EBV infections with or without 1M features have many complications that are primarily categorized by immunopathologic responses to the virus. Among these, autoimmune hemolysis, airway obstruction from enlarged tonsils, splenic rupture, encephalitis, and myocarditis are seen in otherwise healthy patients. Agranulocytosis, aplastic anemia, and other rare but grave features of acute progressive EBV infection occasionally arise in healthy patients and may indicate a demonstrable deficiency of EBV-specific cellular immunity. For such cases, specific antiviral treatment regimens are needed. Acyclovir has anti-EBV-specific activity [4] ; however, despite that disappearance of viral shedding in saliva during treatment of acute 1M, several studies have found no significant effect on individual clinical symptoms [5] [6] [7] [8] . Therefore, it has been suggested that the clinical features of 1M are caused by a characteristic T cell proliferation and activation [20, 21] . We have also found that monocytes/macrophages are constantly involved in the immunopathology of 1M [22, 23] . Steroid therapy may down-regulate production of cytokines in monocytes and also inhibit activation of T cells in certain conditions. Moreover, prednisolone may inhibit EBV-induced autoantibody production, which may be responsible for some complications found in severe 1M cases [24] . The current study sought to determine if combined treatment with acyclovir and steroid could down-regulate the EBV-induced polyclonal activation in acute 1M and also inhibit lytic EBV replication.
Apart from lytic replication in the oropharyngeal epithelium, EBV can transform B cells to proliferating active lymphoblasts first few days of therapy. This could be explained by a direct steroid-mediated antiinflammatory effect in the pharynx mucosa. To see if this trend is statistically significant, further studies of severely unwell 1M patients would be needed. The majority of patients in our study had moderate 1M symptoms. There were no increased adverse events in patients treated with acyclovir-steroid compared with the placebo group.
We conclude that combination therapy with acyclovir and prednisolone is of limited use for patients with mild or moderate 1M symptoms. In severely ill patients, however, steroid treatment may be indicated to prevent incipient airway obstruction. A study of 11 severely ill 1M patients treated in intensive care units showed clinical benefits of such therapy [15] . Further studies are needed of acyclovir-steroid combination therapy in 1M patients with complications requiring intensive care. Such therapy may also be of clinical value in selected cases of cytopenia caused by autoantibody production [24] . In such circumstances, the results of the present study suggest that acyclovir and prednisolone could be given without augmenting the risk of uncontrolled viral replication and without altering the delicate balance between viral latency and specific cellular EBV immunity.
